Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025

12. Boston Scientific Corporation (NYSE:BSX)

Number of Hedge Fund Holders In Q2 2024: 82

Share Price Target Upside: 10%

Share Price Target: $92

Boston Scientific Corporation (NYSE:BSX) is one of the largest medical device manufacturers in the world. It sells items such as stents, catheters, brain stimulation systems, cardiac monitors, and others. It operates in more than 100 countries worldwide and generates $15.2 billion in revenue. Boston Scientific Corporation (NYSE:BSX)’s competitive position in the market is evident through its dominance in technologies such as pulsed field ablation (FPA) which enables physicians to selectively target health tissue while ensuring that the overall organ structure remains intact. Boston Scientific Corporation (NYSE:BSX) launched its Farapulse FPA product in America in January, and in Q2, the device contributed to a 17% revenue growth to the firm’s US revenue. Global regulatory approval of Farapulse can create additional tailwinds for Boston Scientific Corporation (NYSE:BSX), whose shares are up 44% year to date. The market’s optimism surrounding the firm is also visible in its valuation as Boston Scientific Corporation (NYSE:BSX) trades at a forward P/E of 30.49 which is nearly 2x of neer peer Medtronic’s 16.50.

Artisan Partners mentioned Boston Scientific Corporation (NYSE:BSX) in its Q2 2024 investor letter. Here is what the fund said:

“Boston Scientific is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The company develops cardiovascular and cardiac rhythm management products, including imaging catheters, imaging systems and guidewires. It also makes devices used for electrophysiology, endoscopy, pain management (neuromodulation), urology and pelvic health, including laser systems, hydrogel systems and brain stimulation systems. Boston Scientific markets its products in about 130 countries; the U.S. generates about 60% of revenue.

We believe Boston Scientific, as a leader in medical devices, is benefiting from the strong utilization trends coming out of COVID, positive demographic trends with aging patients, and new product innovation to gain market share. The company has executed well against the long-range plan issued last fall, which calls for organic sales growth in the range of 8%-10%, 150 basis points of operating margin expansion and category leadership over the period 2024 through 2026. Additionally, we see a consistent track record of accelerating organic sales growth and a track record of accretive M&A.”